Insmed, a biopharmaceutical company located in Virginia’s Biotechnology Research Park, makes a proprietary delivery compound of insulin-like growth factor-I (IGF-I) bound to its primary binding protein, IGFBP-3. Administered by injection, it’s amazingly versatile; it can: improve blood sugar levels and reduce insulin use in diabetics, improve muscle rebuilding and reduce inflammation in burns, and improve functional recovery and bone mineral density in hip fractures. SomatoKine(R) is now in Phase III clinical trial to help kids with a severe growth disorder–and results are positive.
Insmed’s website has a page where you can get information on licensing, partnering or developing a research collaboration with them.
The debate on how to get ahead in bioscience rages.
An article in today’s Chinese People’s Daily Online says scientists are being told to look for the area where they can take the lead. A professor at Connecticut State University, Yang Xiangzhong urged attendees at a conference in Beijing to focus on embryo technology and cloning. He told them that Americans are going slowly in this area because of ethical and religious disapproval and thus their research is done largely with animals, while China has the advantage of being able to conduct human therapeutic cloning.
Oh, and today’s Washington Post announces that proponents of stem cell research are entering the political fight for the White House.
IBM has just announced a new software solution that “enables research institutions and biopharmaceutical companies across the world to integrate, store, analyze and better understand genotypic and phenotypic data for medical research and patient care.”
The gist of it is that they capture–and de-identify (a new word for the modern security-conscious HIPAA age)–data from existing hospital and research systems, store data from healthcare institutions and diagnostic labs, then centralize it all to yield the opportunity for research on steroids.
Thanks to a tip from an internationally known economic development guru Don Iannone of EdFutures located in Northeast Ohio, we’ve added a link in the Resources area. When you click on “News and Tips for Locating in Europe” you’ll be taken to a site called Techlocate where you can find, oddly enough, news about and tips for locating your life science company–or a branch thereof–in Europe. Imagine…
Hoping to post here an automatically updated list of the interviews we conduct with people who make connections. They’ll be appearing on another site, but I’d like you to be able to link from here. So I hope to get the Atom feed from that site , but right now it’s getting too late to think that much.
Anyway, here are the first two interviews: Mike Burke of Trek Diagnostics, and Steve Goldberg of NEOBio.
Northeast Ohio entrepreneur, Wayne Urban, has done his homework for a couple of years to get this medical device invention off the ground. This truly home-spun, grassroots effort is introducing a product that fills a real need: a sling that holds up your leg when you’ve been injured and can’t stand on it. Makes a lot of sense to podiatrists.
As founder and CEO of his company, LS Products, LLC, Urban did all the investigative research to learn how to get the FDA approval, the manufacturer producing a prototype, etc. “We have demonstrated it, exhibited at medical tradeshows, been featured on TV, and been written up in newspapers. We are adding several sales reps, but we feel we need to reach many more people now,” says Urban.
What better way than to connect through the companies of NEOBio and beyond. Check out their website.
This is really cool. A new stent that can be put in during angioplasty has been designed to prevent the troubling re-narrowing of arteries that seemed always to happen after the procedure. It’s coated with a drug that prevents the restinosis.
Fewer people living additional healthier years without having to have their chests cut open…that’s what the promise of bioscience is about.
The federal government last year distributed $30 billion for highways, $75 billion for weapons systems, and $26 billion for medical research, says a Boston Globe article. Looks like among places to put money that generate local jobs, commerce, and taxes, curing disease comes in last.
Tomorrow Purdue University is hosting a full-day conference-that’s totally free and open to the public–on how bioscience and nanotechnology can be linked. Speakers from Purdue, Northwestern and U of I will talk about current research and discuss how universities can network on this subject.
Oh, and it’s got some heavy-hitter sponsors: Purdue’s Bindley Bioscience Center, Birck Nanotechnology Center, the Network for Computational Nanotechnology (funded by the National Science Foundation), and the Institute for Nanoelectronics and Computing (funded by NASA).
German biotech supplier Eppendorf chose Connecticut as the place to build a new manufacturing facility. What areas were considered and rejected?
The CEO of Eppendorf, which is based in Hamburg, Germany, gave these reasons for the choice: “The Enfield site is closer to the company’s markets, has certain unspecified logistical advantages and less exposure to fluctuations in the currency exchange rate.”